Therapeutically, blocking HVEM–LIGHT co-stimulation might benefit IBD. Conversely, agonists of HVEM’s inhibitory ligand BTLA could mimic HVEM deficiency’s anti-inflammatory effect. Here, BTLA is linked to inflammatory bowel disease.